1 March 2021 in Journal of Perinatology
1 January 2019 in The Journal of Pediatric Pharmacology and Therapeutics
Patients with refractory epilepsy from inborn errors of metabolism typically present as neonates. Direct supplementation with the deficient vitamin or cofactor is recommended, and case series report both efficacy and safety data of these agents. Some conditions may also occur together, necessitating multiple treatments. Despite effective and early treatment, patients are at heightened risk for neurological sequela. The literature on seizures related to metabolic deficiencies for pediatric patients is limited but has some guidance on appropriate dosing and monitoring for agents to target specific deficiencies, which may help with narrowing antiepileptic therapies, reducing side effects, and improving neurodevelopmental outcomes and quality of life. The focus of this review is to discuss the pharmacotherapy, including the most updated published efficacy and safety data, involved in treating refractory epilepsy as a result of metabolic errors.
1 January 2020 in The Journal of Pediatric Pharmacology and Therapeutics
CBCarrie Chalverus Sabrina Boehme
Carrie Chalverus Sabrina Boehme
+285
Article Citation: (2020) Abstracts of the 29th Annual Pediatric Pharmacy Association (PPA) Meeting April 29 to May 3, 2020. The Journal of Pediatric Pharmacology and Therapeutics: 2020, Vol. 25, No. 4, pp. 340-378.
6 October 2025 in American Journal of Perinatology
This study aimed to describe the use of continuous neuromuscular blockade (NMBA) in patients with life-threatening hypoxia and/or hypercarbia secondary to evolving or grade 3 bronchopulmonary dysplasia (BPD) and its association with short-term death, as well as clinical measures of respiratory severity. We identified a cohort of patients with evolving or grade 3 BPD at Riley Children's Health who received continuous infusion vecuronium for greater than 48 hours. We analyzed data using descriptive and inferential statistics. Of the 18 patients identified, 77% survived beyond 7 days after discontinuation of a single course of continuous vecuronium. All but one patient demonstrated decreased respiratory severity score (RSS) and oxygenation saturation index (OSI) across the period of NMBA administration. Mean RSS and OSI decreased significantly across the time of administration (p = 0.003) and was higher in the group that died versus the group that survived (p < 0.001, p = 0.001). Of those that survived to discharge, six received a tracheostomy, and one was discharged in room air. A majority of a cohort of patients with life threatening hypoxia and/or hypercarbia and evolving or grade 3 BPD exposed to continuous NMBA demonstrated a clinically significant incidence of short-term survival and reduced respiratory severity.